InMed Pharmaceuticals (INM) Research & Development (2019 - 2026)

InMed Pharmaceuticals has reported Research & Development for 8 years, with the latest figure at $1.0 million in Q1 2026.

• On a quarterly basis, Research & Development rose 140.41% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 6.17% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, down 11.3% from the prior year.
• Research & Development was $1.0 million for Q1 2026 at InMed Pharmaceuticals, up from $630636.0 in the prior quarter.
• The five-year high for Research & Development was $1.8 million in Q1 2022, with the low at $425370.0 in Q1 2025.
• Average Research & Development over 5 years is $886435.7, with a median of $700145.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Research & Development plunged 66.44% in 2022, then soared 140.41% in 2026.
• Over 5 years, Research & Development stood at $851356.0 in 2022, then declined by 28.37% to $609791.0 in 2023, then jumped by 46.8% to $895176.0 in 2024, then retreated by 29.55% to $630636.0 in 2025, then surged by 62.16% to $1.0 million in 2026.
• The last three Research & Development figures came in at $1.0 million (Q1 2026), $630636.0 (Q4 2025), and $581612.0 (Q3 2025), per Business Quant data.